Corticotropin-releasing factor receptor type 1 (CRF1)

Corticotropin-releasing factor receptor type 1 is a key mediator in the body's response to stress. It belongs to the secretin-like family (class B1) of G protein-coupled receptors and binds corticotropin-releasing factor with high affinity. The receptor is primarily involved in initiating stress responses, while the related CRF2 receptor appears to modulate both the initiation and resolution of stress responses. CRF1 plays a central role in regulating the hypothalamic-pituitary-adrenal axis, which controls the release of stress hormones such as cortisol. The receptor is widely distributed throughout the central nervous system, particularly in regions associated with stress, emotion, and cognition. Dysregulation of CRF1 signaling has been implicated in various stress-related disorders, including anxiety, depression, and addiction. This has made CRF1 an attractive target for therapeutic intervention, with several antagonists in development for treating these conditions. Currently, CRF1 antagonists are FDA-approved for treating congenital adrenal hyperplasia, a rare inherited disorder affecting the adrenal glands. The receptor evolved approximately 500 million years ago from a single CRH-like receptor that subsequently gave rise to both CRF1 and CRF2 forms in vertebrates through gene duplication. This evolutionary history has contributed to the complex and diverse roles of CRF receptors in modern organisms.

Other names

Corticotropin-releasing hormone receptor 1CRHR1CRF1CRF1RCRF receptor 1

CRF1 receptors mediate their effects through G-protein coupled signaling pathways, modulation of cAMP production, and enhancement of GABAergic synaptic transmission (particularly in relation to ethanol effects). Pharmacological targeting with non-peptide CRF1 receptor antagonists typically involves inhibition of CRF-stimulated cAMP production, blockade of CRF-stimulated ACTH release, attenuation of stress-induced elevations in plasma ACTH levels, and inhibition of CRF-induced seizure activity.